COMPANY

Spruce Biosciences

HQ: South San Francisco, CA source · sprucebio.com ↗ · West Coast

Keywords: neurology protein therapeutics mucopolysaccharidosis type IIIB Congenital Adrenal Hyperplasia CAH - Congenital Adrenal Hyperplasia MPS IIIB (Sanfilippo B Syndrome) MPS IIIB 21-OHD Polycystic Ovary Syndrome CAH - 21-Hydroxylase Deficiency Tralesinidase alfa Tildacerfont SPR001

Profile checked Oct 10, 2026

$75.0MRaised (2 yrs)8Trials (company is sponsor)

Timeline

2026-12 Trial start Phase 3: Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) source ↗
Apr 20, 2026 Raise Follow-on offering: $60M (total, as published), announced Apr 20, 2026. Source: SEC filing. source ↗
Jan 8, 2026 Raise Private placement: $15M (initial closing, as published); deal value up to $50M (not counted as received), announced Jan 8, 2026. Source: SEC filing. source ↗
May 15, 2022 Trial start Phase 2: A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens source ↗
Dec 10, 2021 Trial start 2: A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH source ↗
Feb 22, 2021 Trial start Phase 2: A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH source ↗
Aug 26, 2020 Trial start Phase 2: A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH source ↗
Sep 6, 2018 Trial start Phase 2: Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia source ↗
Jul 12, 2017 Trial start Phase 2: Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia source ↗

Upcoming milestones

2033-08 (ESTIMATED) · Phase 3 · Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) · NCT07579910

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $75.0M. Last 2 years.

Apr 20, 2026 Follow-on offering: $60M (total, as published), announced Apr 20, 2026. Source: SEC filing. source ↗
Jan 8, 2026 Private placement: $15M (initial closing, as published); deal value up to $50M (not counted as received), announced Jan 8, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT07733856	Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)	Not listed	Available	Not listed	Not listed
NCT07579910	Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)	Phase 3	Not yet recruiting	2026-12	2033-08 (estimated)
NCT05128942	A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH	2	Terminated	Dec 10, 2021	Jan 31, 2025 (actual)
NCT03257462	Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia	Phase 2	Completed	Jul 12, 2017	Mar 2, 2019 (actual)
NCT05370521	A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens	Phase 2	Terminated	May 15, 2022	Aug 3, 2023 (actual)
NCT04544410	A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH	Phase 2	Terminated	Feb 22, 2021	Oct 31, 2024 (actual)
NCT04457336	A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH	Phase 2	Terminated	Aug 26, 2020	Feb 9, 2024 (actual)
NCT03687242	Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia	Phase 2	Completed	Sep 6, 2018	Jul 8, 2019 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-10-17 Raise Private raise (SEC Form D): $50.0M sold; issuer “SPRUCE BIOSCIENCES, INC.”. Verified from the SEC filing. SEC filing ↗

Connect

Careers page (Oct 8, 2026)